ZA201203795B - Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto - Google Patents

Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Info

Publication number
ZA201203795B
ZA201203795B ZA2012/03795A ZA201203795A ZA201203795B ZA 201203795 B ZA201203795 B ZA 201203795B ZA 2012/03795 A ZA2012/03795 A ZA 2012/03795A ZA 201203795 A ZA201203795 A ZA 201203795A ZA 201203795 B ZA201203795 B ZA 201203795B
Authority
ZA
South Africa
Prior art keywords
vwf
kits
methods
von willebrand
willebrand factor
Prior art date
Application number
ZA2012/03795A
Other languages
English (en)
Inventor
Thomas Barnett
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of ZA201203795B publication Critical patent/ZA201203795B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/03795A 2009-11-13 2012-05-24 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto ZA201203795B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26114509P 2009-11-13 2009-11-13
PCT/US2010/056496 WO2011060242A2 (en) 2009-11-13 2010-11-12 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Publications (1)

Publication Number Publication Date
ZA201203795B true ZA201203795B (en) 2014-10-29

Family

ID=43992414

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/03795A ZA201203795B (en) 2009-11-13 2012-05-24 Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto

Country Status (19)

Country Link
US (1) US8759293B2 (enExample)
EP (1) EP2499165B1 (enExample)
JP (1) JP5876416B2 (enExample)
KR (1) KR101808751B1 (enExample)
CN (1) CN102648212B (enExample)
AU (1) AU2010319425B2 (enExample)
BR (1) BR112012011740A2 (enExample)
CA (1) CA2780542C (enExample)
CL (1) CL2012001258A1 (enExample)
ES (1) ES2600879T3 (enExample)
HU (1) HUE029454T2 (enExample)
IL (1) IL219679A (enExample)
MX (1) MX2012005527A (enExample)
NZ (1) NZ600278A (enExample)
PL (1) PL2499165T3 (enExample)
PT (1) PT2499165T (enExample)
RU (1) RU2579977C2 (enExample)
WO (1) WO2011060242A2 (enExample)
ZA (1) ZA201203795B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
SI2185589T1 (sl) 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
WO2012016073A2 (en) 2010-07-28 2012-02-02 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
BR112015009229B1 (pt) 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
GB201304973D0 (en) * 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2014198699A2 (en) * 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
HK1223303A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 凝血酶可裂解连接子
EP3875106A1 (en) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
US9701933B2 (en) * 2014-09-19 2017-07-11 Sarfaraz K. Niazi Harvesting and purification or perfusion yielder (HAPPY) device
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
SG11201805494WA (en) * 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
BR112019009484A2 (pt) 2016-12-09 2019-07-30 Gliknik Inc otimização de fabricação de gl-2045, um stradomer multimerizador
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
AU2018256453B2 (en) 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
DK3641800T5 (da) 2017-06-22 2024-08-26 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
JP7326246B2 (ja) * 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CA3081106A1 (en) * 2017-11-01 2019-05-09 Queen's University At Kingston Von willebrand factor proteins for treating bleeding disorders
CN112292391A (zh) 2018-03-05 2021-01-29 芝加哥大学 用与细胞因子连接的ecm亲和肽治疗癌症的方法和组合物
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
US10654911B1 (en) 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
CN114173822B (zh) * 2019-06-03 2025-01-10 芝加哥大学 用胶原结合药物载体治疗癌症的方法和组合物
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
KR20250109192A (ko) * 2022-11-14 2025-07-16 셀젠텍크 가부시키가이샤 혈액 응고 제ⅷ 인자 개변체를 산생하는 엑스비보 유전자 치료용 세포
CN116333081B (zh) * 2022-12-27 2025-09-19 大连海洋大学 长牡蛎CgVg功能域DUF1943和VWD重组蛋白及应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234991A (en) 1975-07-29 1993-08-10 Pasteur Merieux Serums And Vaccines Porous mineral support coated with an aminated polysaccharide polymer
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FR2616437B1 (fr) 1987-06-11 1990-09-07 Ibf Polymeres composites, leur preparation et leur utilisation en chromatographie liquide
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5683912A (en) 1994-07-21 1997-11-04 The Salk Institute For Biological Studies Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
WO1993000107A1 (en) * 1991-06-20 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
CA2243560A1 (en) 1996-01-23 1997-07-31 Rapigene, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
DE69734247T2 (de) 1996-07-19 2006-06-22 The Regents Of The University Of Michigan, Ann Arbor Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
US6074832A (en) 1996-07-19 2000-06-13 The Regents Of The University Of Michigan DNA encoding canine von Willebrand factor and methods of use
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AU6782198A (en) 1997-03-27 1998-10-20 Trustees Of Boston University Novel antiplatelet agent
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
NZ501774A (en) 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US7144996B1 (en) 1999-03-05 2006-12-05 Genentech, Inc. Nucleic acid encoding human suppressor of fused
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6664112B2 (en) 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20050153383A1 (en) 2000-07-28 2005-07-14 Montgomery Robert R. Synthetic and recombinant substrates for the detecion of the von willebrand factor-cleaving protease
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003025146A2 (en) 2001-09-18 2003-03-27 Avigenics, Inc. Production of a transgenic avian by cytoplasmic injection
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US20040249134A1 (en) 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) * 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1776389B1 (en) 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007257683A1 (en) 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
KR101627157B1 (ko) 2007-12-27 2016-06-03 박스알타 인코퍼레이티드 샘플 내의 재조합 단백질로부터 혈장-유래 단백질의 분별 방법
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
EP2865760B1 (en) * 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ

Also Published As

Publication number Publication date
CA2780542C (en) 2020-03-24
MX2012005527A (es) 2012-08-08
CL2012001258A1 (es) 2012-09-14
CN102648212B (zh) 2014-12-03
EP2499165A4 (en) 2013-09-11
IL219679A0 (en) 2012-07-31
JP5876416B2 (ja) 2016-03-02
NZ600278A (en) 2014-04-30
HUE029454T2 (en) 2017-03-28
KR20120113214A (ko) 2012-10-12
PT2499165T (pt) 2016-10-28
AU2010319425B2 (en) 2015-07-02
BR112012011740A2 (pt) 2018-03-27
US8759293B2 (en) 2014-06-24
RU2012122402A (ru) 2013-12-20
CN102648212A (zh) 2012-08-22
JP2013510581A (ja) 2013-03-28
US20120289468A1 (en) 2012-11-15
ES2600879T3 (es) 2017-02-13
KR101808751B1 (ko) 2017-12-13
EP2499165A2 (en) 2012-09-19
AU2010319425A1 (en) 2012-06-14
CA2780542A1 (en) 2011-05-19
RU2579977C2 (ru) 2016-04-10
WO2011060242A3 (en) 2011-10-13
HK1170244A1 (zh) 2013-02-22
EP2499165B1 (en) 2016-09-14
WO2011060242A2 (en) 2011-05-19
IL219679A (en) 2016-11-30
PL2499165T3 (pl) 2017-04-28

Similar Documents

Publication Publication Date Title
IL219679A0 (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
IL236412B (en) Complex of factor viii with castane and factor von Willebrand protein and uses thereof
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
GB2478230B (en) Gesture based edit mode
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
IL226383A0 (en) Antibodies against ccl20, preparations containing them and their uses
ZA201208578B (en) Composition,method and use
ZA201008682B (en) Textile complex,communication panel and method of displaying the textile complex
ZA201302099B (en) Immunochromatography devices,methods and kits
GB2497478B (en) Substrate with built-in component, and method the same
IL193701A0 (en) Luminescent solar concentration
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
TWI370040B (en) Simultanes doppelseitenschleifen von halbleiterscheiben
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
IL216731A (en) And antibodies against p95 – her2 and their uses
EP2601235A4 (en) EPOXYED COMPOSITION AND METHOD OF MANUFACTURING THEREOF
PL2078730T3 (pl) Sposób otrzymywania koncentratu czynnika von Willebranda lub kompleksu czynnik VIII/ czynnik von Willebranda oraz ich zastosowanie
EP2618326A4 (en) PORTABLE TERMINAL, ITS CONTROL METHOD AND PROGRAM
IL236236A (en) Antibodies to the fam26f polypeptide
WO2012050963A3 (en) Agents providing controls and standards for immuno-precipitation assays
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
EP2193373A4 (en) METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
IL226498A0 (en) 177 lutetium-labeled bombesin analogs, kits comprising the same and uses thereof
PL2262828T3 (pl) Kompozycje, sposoby i zestawy